Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.49 |
| ▸ | HRH1 | P35367 | 7/20 | 0.43 |
| ▸ | HTR6 | P50406 | 6/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 4/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293817 | 0.94 | HDAC6 (0.42) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL12820018 | 0.94 | HDAC6 (0.41) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL169212 | 0.90 | HDAC6 (0.51) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL10315934 | 0.90 | HDAC6 (0.49) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL17518569 | 0.89 | HDAC6 (0.47) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL168439 | 0.89 | HDAC6 (0.52) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL168622 | 0.87 | HDAC6 (0.48) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL13293835 | 0.84 | BAZ2B (0.44) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL13306339 | 0.84 | HDAC6 (0.42) | HDAC6HDAC1HRH1HTR6BAZ2B | |
| SCHEMBL12820340 | 0.84 | HDAC6 (0.43) | HDAC6HDAC1HRH1HTR6BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | claimed |
| US-8927571-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-01-06 | — | — | US | claimed |
| US-8741919-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-03 | — | — | US | claimed |
| US-20130190331-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | claimed |
| EP-2424366-A1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2011019417-A1 | PYRIDO [4, 3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-02-17 | — | — | WO | claimed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2424366-B1 | PYRIDO [4, 3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172377-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HDAC6 3393/4885HDAC1 4018/4885HRH1 41/4885 |
| US-20130190331-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HDAC6 3393/4885HDAC1 4018/4885HRH1 41/4885 |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HDAC6 2844/4885HDAC1 1375/4885HRH1 93/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HDAC6 2844/4885HDAC1 1375/4885HRH1 93/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | HDAC6 3097/4885HDAC1 2415/4885HRH1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.